The study, which was conducted from Oct 1 to Nov 21, involved people aged 40 and above who received two doses of the vaccines under the national vaccination programme.
Of the 1.25 million people covered in the study, 62,900 had COVID-19 and 1,710 were considered severe cases.
Most of them - 73.7 per cent - took the Pfizer-BioNTech/Comirnaty vaccine, while 23.9 per cent received the Moderna shots and 2.4 per cent received the Sinovac vaccine.
"The analysis accounted for differences in age, gender, race, housing type and the daily differences in infection rate," said NCID and MOH.
They recommended that those who have already received two doses of the Sinovac vaccine get a dose of an authorised mRNA vaccine as the third dose of their primary vaccination series.
"Otherwise, they should complete their primary series with a third dose of the Sinovac-CoronaVac."
https://news.google.com/__i/rss/rd/articles/CBMicWh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vc2luZ2Fwb3JlL3Npbm92YWMtY292aWQtMTktdmFjY2luZS1sb3dlci1wcm90ZWN0aW9uLW1ybmEtdmFjY2luZS1uY2lkLW1vaC0yMzgxOTc20gEA?oc=5
2021-12-15 13:32:07Z
1200440287
Tidak ada komentar:
Posting Komentar